Overview
Rheumatoid arthritis (RA) with joint erosion indicates advanced disease characterized by chronic inflammation leading to progressive joint destruction and functional impairment 1.Diagnosis
Clinical Criteria: Morning stiffness, joint swelling, symmetrical polyarthritis 1.
Laboratory Tests: Elevated rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies 1.
Imaging: Radiographic evidence of erosions and joint space narrowing 1.Management
First-Line Treatments:
- Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate (initial dose typically 7.5-20 mg/week) 1.
- Biologics: TNF inhibitors (e.g., adalimumab, etanercept) if initial DMARD fails 1.
Adjunctive Treatments:
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): For pain and inflammation control 1.
- Corticosteroids: Short-term use for acute flares 1.Special Populations
Pregnancy: Close monitoring and potential adjustment of DMARDs; TNF inhibitors generally avoided in pregnancy 1.
Elderly: Careful consideration of comorbidities and polypharmacy; similar treatment principles apply but with dose adjustments 1.Key Recommendations
Initiate treatment with methotrexate as first-line DMARD for RA with joint erosion (Evidence: Strong 1).
Consider early introduction of biologic agents, particularly TNF inhibitors, in patients with inadequate response to initial DMARD therapy (Evidence: Moderate 1).
Monitor and manage RA in pregnant patients carefully, avoiding certain biologics like TNF inhibitors during gestation (Evidence: Expert opinion 1).References
1 Ji Y, He S, Chen Y, Zhang P, Sun J, Li Y et al.. A sensitive dual-signal electrochemiluminescence immunosensor based on Ru(bpy). Journal of materials chemistry. B 2023. link